Difference between revisions of "Team:UCL/Alphabrick"

Line 7: Line 7:
 
     <ul>
 
     <ul>
 
         <li><a href="#summary">Summary</a></li>
 
         <li><a href="#summary">Summary</a></li>
         <li><a href="#concept">Concept</a></li>
+
         <li><a href="#problem">Problem</a></li>
         <li><a href="#potential">Potential</a></li>
+
         <li><a href="#solution">Solution</a></li>
 +
        <li><a href="#ip">IP</a></li>
 +
        <li><a href="#manufacturing">Manufacturing</a></li>
 +
        <li><a href="#market_analysis">Market Analysis</a></li>
 +
        <li><a href="#marketing">Marketing</a></li>
 
         <li><a href="#business">Business</a></li>
 
         <li><a href="#business">Business</a></li>
         <li><a href="#team">Team</a></li>
+
         <li><a href="#management">Management</a></li>
         <li><a href="#funding">Funding</a></li>
+
         <li><a href="#financial">Financial</a></li>
 
+
 
     </ul>
 
     </ul>
 
</div>
 
</div>
Line 21: Line 24:
 
         <div class="ess-template-page">
 
         <div class="ess-template-page">
  
             <div style="background-image: url('https://static.igem.org/mediawiki/2016/0/0d/T--UCL--Automation.png');"
+
             <div style="background-image: url('https://static.igem.org/mediawiki/2016/9/90/T--UCL--Michelle.png');"
 
                 class="ess-template-fixed-bgd-section">
 
                 class="ess-template-fixed-bgd-section">
 
                 <div class="container">
 
                 <div class="container">
 
                     <div class="col-md-12 text-center animate-box">
 
                     <div class="col-md-12 text-center animate-box">
                         <h1 style="color: white"><span style="background-color: #004574">ALPHABRICK</span></h1>
+
                         <h1 style="color: white"><span style="background-color: #004574">XWEET</span></h1>
 
                     </div>
 
                     </div>
 
                 </div>
 
                 </div>
Line 39: Line 42:
  
 
             <div class="ess-template-general-section">
 
             <div class="ess-template-general-section">
 
 
                 <div class="row">
 
                 <div class="row">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 
                         <div id="summary" class="vertical-scroll-section">
 
                         <div id="summary" class="vertical-scroll-section">
 
                             <div class="content">
 
                             <div class="content">
                                <h2> <center> 1. Executive Summary </center> </h2>
+
                        <h2> <center> 1. Executive Summary </center> </h2>
                                <h4> AlphaBrick is a novel software tool for the easy design, exchange and creation of synthetic gene constructs. </h4>
+
                        <br>
                                <br>
+
                        <h4> Xylitol is a sugar polyol that has been used in the food industry as a low-caloric sweetener. It has been reported to have multiple beneficial health effects such as the prevention of dental caries, osteoporosis, and acute otitis media. Currently, xylitol is commonly produced by the chemical reduction of xylose presented in xylans. However, this process represents substantial costs for the industry. We have designed a genetic circuit for the expression of the necessary enzymes for the biological production of xylitol from lignocellulose hydrolysates for expression in E. coli for fermentation and subsequent processing.  </h4>
                                <h4> Recent advances in the synthetic biology field, such as with the Crisper/Cas9 system, have dramatically increased the potential of synthetic biology technologies to transform our world. We can now use our biological understanding to create products that solve some of the biggest challenges the world faces. These advances, however, require a new set of accessible computational tools that enable the synthetic biologist to quickly and collaboratively design and test DNA circuitry. </h4>
+
                        <br>
                                <br>
+
 
                                <h4> Employing a lean methodology, we have identified the three key problems faced by the synthetic biology community. Currently, (1) the design of gene circuits is complex because collaboration between and within teams is difficult and thought processes are lost, (2) exchange of gene circuit parts is messy, as you have to individually track and hunt down the person who created it and (3) individuals have to have an advanced understanding of programming languages to use automated labs. </h4>
+
                        <h4> We have also created a comprehensive first iteration of a business plan for the production of Xweet, a key ingredient in tooth-decay defying sweets. We have filed a provisional patent and trademarked our more environmentally friendly method for the production of Xweet. Adopting a lean method, we have engaged extensively with the confectionary industry, prototyping Xweet confectionery and setting out a pathway for commercial success. </h4>
                                <br>
+
 
                                <h4> Our software platform solution, Alpha Brick, originated at the UK’s first 72-hour bio-hackathon at which it won first place. AlphaBrick allows synthetic biologists to easily design, exchange and create DNA circuitry. The platform enables users to experience a quicker, traceable design process that ensures that decisions are recorded and that subsequent progress is accelerated. It provides a marketplace for lab designs by facilitating the buying and selling of gene circuit parts, making collaboration easier. The integration of the AlphaBrick platform with Transcriptic’s automated laboratories saves precious time and reduces the knowledge-barrier to using robotic labs. Our platform’s patent notification and parts combination recommendation, furthermore, address an unmet need of biotech industry that we identified through industry interviews. We envisage that AlphaBrick will have a big impact on accelerating synthetic biology research and commercialisation.  </h4>
+
                        <br>
                                <br>
+
                        <center> <img src = "https://static.igem.org/mediawiki/2016/e/e9/T--UCL--XweetLogo.png"> </center>
                                <h4> The synthetic biology community of biohackers, academics, startups and established biotech companies who have these problems is growing quickly and the current tools available don’t address these concerns in an integrated way. There is space in this is $1.2 billion market for an easy to use tool that allows high share ability of gene circuitry. The platform will be commercialised such that users will be required to pay a monthly subscription fee at the average market rate for the platform’s premium features. </h4>
+
                        <br>
                                <br>
+
                                <h4> Our multidisciplinary team consists of developers, biologists and entrepreneurs and can be broadly stratified into product development and business development. The current team was formed at the Cambridge University Technology and Enterprise Club’s 2016 Bio hackathon. Our 4 co-founding members are working to establish AlphaBrick as an incorporated software company. </h4>
+
                                <br>
+
                                <h4> Working through the prestigious Accelerate Cambridge programme, we envisage that our alpha-version will be ready for distribution in January 2017 and that our final product will be ready for launch in June 2017. In order to ensure the progression of our venture, Alphabrick are looking to raise £20,000 in pre-seed from angel investors funding or non-dilutive funding by the start of February 2017. </h4>
+
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
 
                 </div>
 
                 </div>
 
                <br>
 
                <br>
 
  
 
                 <div class="row">
 
                 <div class="row">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
                         <div id="concept" class="vertical-scroll-section">
+
 
 +
                         <div id="problem" class="vertical-scroll-section">
 
                             <div class="content">
 
                             <div class="content">
                                <h2> <center> 2. Product Concept  </center> </h2>
+
 
                                <h3> The Problem </h3>
+
                        <h2> <center> 2.   The problem explored </center> </h2>
                                <br>
+
 
                                <h4> Recent advances in the $6.4 billion synthetic biology field have dramatically increased the potential of synthetic biology technologies to transform our world. We can now use our biological understanding to create products that solve some of the biggest challenges the world faces. We have adopted a strong lean methodology to identify that these advances have also lead to a currently poorly met need for a new set of accessible computational tools that enable the synthetic biologist to quickly and collaboratively design and test DNA circuitry. </h4>
+
                        <br>
                                <br>
+
                        <h4> Through our engagement with our local elderly community we identified a demand for tea-time treats that did not cause tooth-decay or imbalances in sugar levels. Adopting a lean method, we have engaged extensively with the confectionary industry to explore London’s sugar-substituted sweet landscape to confirm this as a wider demand. Our extensive literature search drew our attention to xylitol, a sugar substitute with widely-reported health benefits but an environmentally unfavorable and expensive production process. Xylitol is a key ingredient in tooth-decay defying sweets. Speaking to the UK’s confectionary manufacturers, we confirmed demand for xylitol produced in a less expensive and more environmentally friendly way. </h4>
                                <h4> Through extensive interviews with the synthetic biology community, we have sought to verify every one of our business hypothesis to generate evidence-based identification of the pains of each our customer segments and the value propositions that they care most about. By talking to 69 iGEM teams, 7 synthetic biology startups, the UK’s world leading synthetic biology labs and a major world pharmaceutical R&D lab, we have been able to identify the key pain points in the work flow of synthetic biology users. This has informed and shaped our continuously changing business model canvas, the staple tool of all startups in search of a viable and scalable business model. </h4>
+
                        <br>
                                <br>
+
 
                                <center> <img src = "https://static.igem.org/mediawiki/2016/0/07/T--UCL--alphabrick1.png"> </center>
+
                        <h3> Demand for tooth-decay defying treats from end users </h3>
                                <br>
+
                        <br>
                                <center> <img src = "https://static.igem.org/mediawiki/2016/f/f0/T--UCL--AlphaPics.png"> </center>
+
                        <h4> London’s ageing population have a sweet tooth. Reports show that this is due to the impact that ageing has on our taste buds. Over time our taste buds decrease in number and become less sensitive. This is compounded by the effect of age-related diseases such as Alzheimer’s and Parkinson’s Disease, with the loss of taste and smell actually becoming increasingly important in the diagnosis of these disease. This drives the increasingly sweet tooth of the ageing population which in turn drives a negative impact on the oral health of this population. The oral disease burden, of which a big part is attributable our ageing population, is causing the total oral health expenditure within the EU to rise to an enormous €93 billion in 2020. There is therefore a push in public health policy towards preventative solutions that minimize bad oral health manifested in large parts as dental caries. This demand for tooth-decay defying sweets was therefore flagged up to us through our engagement with the elderly community. They described their need for sweet treats and oral health as a constant pain throughout their ageing process. </h4>
                                <p> </p>
+
 
                                <br>
+
                        <br>
                                <h4> The three key pains of most of our customer segments within the synthetic biology community are that (1) the design of gene parts is complex because collaboration between and within teams is difficult and thought processes are lost; (2) exchange of gene circuit parts is messy, as you have to individually track and hunt down the person who created it and (3) individuals have to have an advanced understanding of programming languages to use automated labs. Our customer interviews, moreover, elucidated nuances in the pains felt by our customer segments: while most of our customers would benefit from easier access to automated cloud labs to reduced labour costs and the time taken to run manual experiments, some of customers, and arguably our most important customers in terms of purchasing power, would not benefit from this due to worries over intellectual property and trade secrets. From talks with a major pharmaceutical and biotech company, we also identified a fourth pain point, (4) the need for notifications about patented sequences and readily available information about part combinations. </h4>
+
                        <center> <img src = "https://static.igem.org/mediawiki/2016/2/25/T--UCL--dementiahome2.png " > </center>
                                <br>
+
                        <br>
                                <center> <img src = "https://static.igem.org/mediawiki/2016/a/a9/T--UCL--alphabrick2.png"> </center>
+
 
                                <p> </p>
+
                        <h3> Demand for tooth-decay defying treats from confectionery retailers </h3>
                                <h3> Our Solution </h3>
+
                        <h4> We confirmed this demand for tooth-decay defying treats through interviews with London’s sweet landscape. We identified that these outlets were experiencing a shift in their customer demands such that there is an increasingly underserved proportion of health-conscious sweet lovers. Some of the sweet shops that we interviewed made their own sweets, while most bought their sweets from confectionary manufacturers. While the total EU and US confectionary market it worth €66.75 billion, the healthy confectionary market has been increasing its share of this overall market in recent years, putting the latest market share estimate within the UK at 11%. The growth of the healthy confectionary market is 16% higher than the total average growth of the entire confectionary market. These confectionary outlets provided us with a list of sugar-substitutes that customers ask for and that are used in the production of these sweets. We partnered with staff to identify xylitol through this market research and an extensive literature search as a candidate for meeting this demand. D-Xylitol is a sugar polyol that has been used in the food industry as a low-caloric sweetener.  It also has been reported as having multiple beneficial health effects such as the prevention of dental caries, osteoporosis, and acute otitis media. </h4>
                                <br>
+
 
                                <h4> We have therefore founded Alphabrick, a software tool interfacing automated cloud labs, for the design, exchange, and creation of synthetic gene constructs. Our software platform solution, www.alphabrick.bio,  originated at the UK’s first 72 hour biohackathon at which it won first place.  </h4>
+
                        <br>
                                <br>
+
                        <center> <img src = "https://static.igem.org/mediawiki/2016/5/5c/T--UCL--Sweetshops.png" > </center>
                                <center> <img src = "https://static.igem.org/mediawiki/2016/6/61/T--UCL--alphabrick3.png"> </center>
+
                        <br>
                                <br>
+
 
                                <h4> AlphaBrick allows synthetic biologists to easily design, exchange and create DNA circuitry. The platform enables users to experience a quicker, traceable design process that ensures that decisions are recorded and that subsequent progress is accelerated. It provides a marketplace for lab designs; by facilitating the buying and selling of gene circuit parts, making collaboration easier. The integration of the AlphaBrick platform with Transcriptic’s automated laboratories saves precious time and reduces the knowledge-barrier to using robotic labs. Given our customer interviews, we envisage that this platform will have a big impact on accelerating SynBio research and commercialisation. </h4>
+
                        <br>
                                <br>
+
                        <h3> Demand for tooth-decay defying ingredients from confectionery manufacturing industry </h3>
                                <h4> We demoed a successful run of our first prototype and MVP with a use-case at the Cambridge Biohackathon using Transcriptic’s automated cloud lab work cell in July of this year. </h4>
+
                        <br>
                                <br>
+
                        <h4> Our literature research highlighted the potential of xylitol for use in tooth-decay defying sweets. It’s health benefits and positive impact on dental caries have been widely reported. We explored how xylitol is used in confectionary manufacturing to understand how more confectionary manufacturers can be enabled to use xylitol in their production processes. By visiting a chocolate manufacturing company, discussing their production process with the Operation Manager and observing their production process, we were able understand the decision making process in raw material procurement and the parameters for consideration of the material in the process. Most notably, we discovered that manufacturers prefer to use xylitol over other sugar substitutes such as coconut sugar as xylitol’s high melting temperatures makes it a manufacturer’s dream when making chocolate treats as machinery is not clogged up with caramel. However, the manufacturers hold back from using xylitol because of its associated costs and environmental impact. </h4>
                                <center> <video width="600" height=400" controls>
+
 
                                    <source src="https://static.igem.org/mediawiki/2016/8/87/T--UCL--alphabrick4.mp4" type="video/mp4">
+
                        <br>
                                </video> </center>
+
                        <center> <img src = "https://static.igem.org/mediawiki/2016/7/75/T--UCL--ChocFac.png"> </center>
                                <br>
+
                        <br>
                                <h4> We have since been working to expand the capabilities of our platform. Our product development team are hard at work on algorithms for effective recommendations for the best combination of constructs when designing a DNA circuit as well as data-mining solutions for notifications about patented DNA sequences. </h4>
+
 
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 
                     </div>
 
                     </div>
 
                 </div>
 
                 </div>
 
                <br>
 
                <br>
 
  
 
                 <div class="row">
 
                 <div class="row">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
                         <div id="potential" class="vertical-scroll-section">
+
 
 +
                         <div id="solution" class="vertical-scroll-section">
 
                             <div class="content">
 
                             <div class="content">
                                <h2> <center> 3. Commercial Potential  </center> </h2>
 
                                <h3> Market Opportunity </h3>
 
                                <br>
 
                                <h4> As synthetic biology technology has been developing even quicker than that predicted by Moore’s Law, the $6.4 billion synthetic biology market is set to grow by one of the biggest compound annual growth rates (CAGRs) of any field. The synthetic biology market will make up 6% of the total biotech market. Considering the value system and chains within the synthetic biology field’s workflow, it is clear that there is trapped value with regards to the effieicney, accessibility and user empowement that can be addressed by new computational biology solutions such as AlphaBrick. The computational biology market is set to grow by 21% from it’s current $1.7 billion valuation. This therefore presents an immensely profitable potential market opportunity for Alphabrick. </h4>
 
  
                                <br>
+
                        <h2> <center> 3. Our Solution  </center> </h2>
                                <center> <img src = "https://static.igem.org/mediawiki/2016/e/ee/T--UCL--alphabrickcircle.png" > </center>
+
                                <br>
+
  
                                <br>
+
                        <h4> We have therefore identified trapped value where in the value chain from feedstock to production of tooth-decay defying treats. We are best placed to solve this problem and have devised a plan for the production of xylitol, using synthetic biology and biochemical engineering processes, that reduces the impact on the environment and decreases associated costs. Our solution aims to supply a big proportion of the global market demand for more than 125,000 tonnes of xylitol per annum.</h4>
                                <h3> Competitor Analysis </h3>
+
 
                                <br>
+
                        <br>
                                <h4> An analysis of the competitive landscape into which Alphabrick will be released has proved favourable. Alphabrick’s platform, as a whole, does not have direct competitors as there is no commercially available platform that integrates the pains that Alphabrick addresses. When broken down, however, into the individual features that it offers the user, it can be understood to have a number of indirect competitors in the DNA sequence design and automated creation space. While DNA sequences can be designed for the specific purposed of using the Crisper/Cas9 system with Desktop Genetics and more broadly with Benchling, these software solutions do not have the extensive gene construct combination recommendation or patent notification that our platform has. Furthermore, these platforms do not interface with automated laboratories. These automated laboratories are partners of our software platform as our platform directs business to their way. Furthermore, currently widely used synthetic biology tools such as SnapGene and APE do not have the intuitive user interface that reduces barriers to entry for new synthetic biologists. The combined share ability and usability that our platform enables is unprecedented. There is therefore space for AlphaBrick in this competitive landscape. </h4>
+
                        <center> <img src = "https://static.igem.org/mediawiki/2016/6/69/T--UCL--SupplyChain.png"> </center>
                                <br>
+
                        <br>
                                <center> <img src = "https://static.igem.org/mediawiki/2016/5/5d/T--UCL--alphabrickdiageam.png" > </center>
+
 
                                <br>
+
                        <br>
                                <h3> Intellectual Property </h3>
+
                        <h4> Our solution for the production of xylitol for supply to confectionery manufacturer involves a synthetic gene circuit in E. coli for extracellular secretion of xylitol following processing of xylan from agricultural waste in the upstream process. The downstream process involves a series of biochemical extraction and purification steps, using drastically less energy than the chemical process for xylitol production. Our xylitol product, Xweet, can be used to produce tooth-decay defying confectionery treats that utilise xylitol, at a lower price and incredibly similar taste to conventionally sugared treats. </h4>
                                <br>
+
                        <br>
                                <h4> Alphabrick’s intellectual property has thus far been protected by trade secrets and copyrights. We are working to obtain legally binding trademarks with the UK Intellectual Property Office for our platform through advice and mentorship from Accelerate Cambridge, the accelerator programme on which we have been accepted. </h4>
+
 
                                <br>
+
                        <h4> We prototyped a potential treat that could be made with our xylitol product. We cooked up fudge using conventional brown sugar and xylitol. We asked UCL students to compare the tastes of our two batches, two identify the better tasting batch and the one that they thought contained xylitol. 100% of all participants guessed incorrectly, failing to identify the xylitol batch correctly. This lends support to the potential for xylitol to replace sugar in a vast number of confectionery products. </h4>
                                <h4> Our platform layout and written content is automatically covered by UK copyright protection law. Alphabrick has signed a series of non-disclosure agreements (NDAs) with all potential investors and mentors with which we have shared sensitive information about our platform and features. Alphabrick’s platform is also built using closed code and therefore trade secrets form a big part of our intellectual property protection strategy. Trade secrets give us a competitive advantage when it comes to protecting our algorithms because it means that we don’t have to publish and make public sensitive aspects of our platform. While common in the biotech field, patents in the software field are contentious and since the Alice Corp. v. CLS Bank software infringement case ruling, the software patent landscape has shifted considerably such that patenting in this field is rarely the best intellectual property protection strategy to pursue. This is very pertinent to AlphaBrick especially given the early stage of this startup and the large costs associated with engaging with
+
                        <br>
                                    patent attorneys. By using trade secrets, AlphaBrick is however at risk if our code is discovered independently, if our platform is reverse-engineered and/if companies who later patent a similar technology take patent infringement actions. We have sought to mitigate the likelihood of these risks occurring by safeguarding our code using firewalls and working with Accelerate Cambridge to develop a sound long-term intellectual property strategy. </h4>
+
                        <br>
                                <br>
+
                        <center> <img src = "https://static.igem.org/mediawiki/2016/b/b3/T--UCL--Fudge.png"> </center>
                                <h3> Pathway to Commercialisation</h3>
+
                        <br>
                                    <br>
+
 
                                    <h4> Alphabrick are progressing through the prestigious Accelerate Cambridge programme at Cambridge University’s Judge Business School to identify the best pathway to commercialisation of the software platform. By 2017, the initial funding obtained for the platform and founder resources are set to run out. Due to this, the team will be raising pre-seed funding in November to continue and prepare for the launch of the alpha version of the platform by January 2017.  The marketing strategy for the launch of the final product will build on the traction gained via users of the alpha and beta versions. Alphabrick has already achieved a formidable network within the biotech community and industry for its early stages, it will harness this to gain the breadth of selected users it needs to complete an initial alpha testing phase. The feedback from this phase will shape the beta version which will be released to a yet bigger number of users to ensure that the platform is ready for product launch in June 2017. The model for the revenue stream for Alphabrick will be from subscription fees paid by users to unlock premium features on the software platform. </h4>
+
                        <h4> Using our upstream technology in a novel method for the production of xylitol from agricultural waste reduces the cost of the final product and the environmental impact. This therefore means that we are able to sell xylitol to confectionary manufacturers and the pharmaceutical industry for who the value proposition of reduced cost of raw materials and the reduced carbon footprint of their final product lifecycle contributes to the increase in profit margins. By making xylitol purchasing cheaper, moreover, we are empowering confectionary manufacturers to meet the demands of an ageing population for tooth-decay defying treats. We therefore have a unique and defendable business case. </h4>
  
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
 +
 
                     </div>
 
                     </div>
 
                 </div>
 
                 </div>
  
                <br>
 
                <br>
 
  
 
                 <div class="row">
 
                 <div class="row">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
  
                         <div id="business" class="vertical-scroll-section">
+
                         <div id="ip" class="vertical-scroll-section">
 
                             <div class="content">
 
                             <div class="content">
                                <h2> <center> 4. Business Environment </center> </h2>
+
 
                                <h4> Alphabrick’s resources, as a startup, are geared towards the realisation of a rolling series of short-term goals that are necessary for the survival of a cash-strapped venture. However, a consideration of the long-term, external and internal, issues that may arise and hinder or help Alphabrick’s progression to a fully-fledged synthetic biology software company is undertaken here to evaluate Alphabrick’s longer-term business environmentA STEEPLE framework which in its augmented form encompasses a PEST (political, economic, social and environmental) and SWOT (strengths, opportunities, weaknesses, threats) analysis, is used her evaluate external and internal points of possible concern for Alphabrick. </h4>
+
                        <h2> <center> 4. Intellectual Property  </center> </h2>
                                <br>
+
                        <h4> Because of its technological relevance and its disclosure in this event, having an intellectual property strategy was crucial for the commercial aspects of the project. This approach has been confirmed after several discussions with numerous potential investors and advisers. Two important intellectual property figures were considered for this project, a patent and a trademark.</h4>
                                <center> <img src = "https://static.igem.org/mediawiki/2016/0/00/T--UCL--alphabrick7.png"> </center>
+
                        <br>
                                <br>
+
                        <h3> Patent </h3>
 +
                        <br>
 +
                        <h4> Initially, we performed a search in the database (Espacenet) from the European Patent Office. The results were encouraging because no result was similar to our invention after using (in different combinations) the keywords: xylitol, cell, surface, display. However, considering the possibility of not complying with the novelty feature, we searched for scientific articles that could describe a similar technology. From the results, we found that Guirimand et al. published in 2015 a similar system. The researchers reported the surface display of four enzymes (Xylose reductase, ß-glucosidase, xylosidase and xylanase) on yeast for the conversion of xylans into xylitol. Despite its likeness, our proposed project differs in (1) the displayed enzymes, (2) the host organism, (3) the oscillating phenotype of the enzymatic expression. Following this, we found that our invention could fulfill the three patent features and therefore our invention was fully patentable.
 +
                            This intellectual property search allowed us to define the claims for our patent application. We filed a provisional patent application with the UK Intellectual Property Office using the presented form with the application number 1616500.3. The relevant documents for this application are presented below: </h4>
 +
                        <br>
 +
                        <h4> This intellectual property search allowed us to define the claims for our patent application. We filed a provisional patent application with the UK Intellectual Property Office using the presented form with the application number 1616500.3. The relevant documents for this application are presented below: </h4>
 +
                        <br>
 +
                        <h4>
 +
                            1. <a href = "https://static.igem.org/mediawiki/2016/5/5e/T--UCL--Form.pdf"> Filed Form </a> </h4>
 +
                        <h4>
 +
                            2. <a href = "https://static.igem.org/mediawiki/2016/b/be/T--UCL--Patent.pdf">  Receipt </a> </h4>
 +
                        <br>
 +
                        <h4> We are currently working on an international patent application (PCT) for our invention. This strategy grants us additional time for starting patent applications simultaneously in 140 countries.</h4>
 +
                        <br>
 +
                        <h3> Trademark </h3>
 +
                        <br>
 +
                        <h4> Continuing with our intellectual property strategy, we have been working on filing a trademark application with the UK Intellectual Property Office for the brand and the logo of our final product, Xweet. This allows us to distribute an early version of the product to different stakeholders while building a product identity. </h4>
 +
 
 +
                            </div>
 +
                        </div>
 +
 
 +
                    </div>
 +
                </div>
 +
 
 +
                <div class="row">
 +
                    <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 +
 
 +
                        <div id="manufacturing" class="vertical-scroll-section">
 +
                            <div class="content">
 +
 
 +
                        <h2> <center> 5. Manufacturing operations  </center> </h2>
 +
                        <br>
 +
                        <h3> Upstream: Feedstock </h3>
 +
                        <br>
 +
                        <h4> One challenge in the production of Xylitol is to find an adequate source. As mentioned before, purified D-Xylose is used for the chemical and enzymatic production. However, the use of agricultural waste for the manufacture of Xylitol has become a milestone in this field. </h4>
 +
                        <br>
 +
                        <h4> Most of the agricultural waste can be divided in cellulose, hemicellulose, and lignocellulose. Lignocellulosic biomasses (LBs) are widespread, abundant, renewable, cost-effective, and economical sources of polysaccharides, which can be used for xylitol production. These sources include agricultural, agro-industrial, and forestry These residues contain lignocellulose, organic matter that is mainly composed of cellulose (34–50%), hemicellulose (19–34%), lignin (11–30%), and smaller amounts of pectin, protein, extractive, and ashes. The composition of these components differs with the source of plant species, age, and growth conditions. The most abundant heterogeneous polymer of LBs is hemicellulose, which comprises of pentoses (xylose and arabinose), hexoses (mannose, glucose, and galactose), and residues. Sugar acids. We are considering the use of the LB hydrolysates as Xylan source and fundamental part of the proposed system. </h4>
 +
                        <br>
 +
                        <h3> Upstream: Inoculum strain for bioconversion during fermentation </h3>
 +
                        <h4> Currently, D-Xylitol is commonly produced by the chemical reduction of D-Xylose presented in xylans in the presence of a nickel catalyst at elevated temperature and pressure. However, this process represents substantial costs for the industry. A proposed alternative for the chemical hydrolysis is the conversion of this pentose by the use of enzymes or microorganisms. Nonetheless, the biological fermentation presents some issues such as accumulation of the metabolite at toxic levels or challenges with the purification process. Additionally, the use of enzymes may represent a higher cost because of the production and purification of such proteins.</h4>
 +
                        <br>
 +
                        <h4> The bioprocess for xylitol production that we are presenting is based on the expression of cell surface displayed enzymes. The enzymes in this system are described in the next table: </h4>
 +
                        <br>
 +
                        <center> <img src = "https://static.igem.org/mediawiki/2016/a/a2/T--UCL--Table.png"> </center>
 +
                        <br>
 +
                        <h4>
 +
                            In this case, the enzymes involved in the degradation of xylan and the subsequent xylitol transformation are fused to the ß-domain of the autotransporter EspP. The fusion proteins would be expressed in E. coli and be able to anchor to the outer membrane. The advantage of this system is the avoidance of purification steps. However, some issues should be taken on account such as required cofactors or the presence of disulphide bonds.
 +
                        </h4>
 +
                        <br>
 +
                        <h4>
 +
                            Because of possible membrane instability, the expression of these enzymes is controlled by a genetic circuit. The proposed genetic circuit would function as an oscillator by expressing constitutively on the surface the enzymes XynA, Aes and Ruxyn1. The expression of these enzymes would trigger the degradation of Xylans into monomers from the lignocellulosic hydrolysates by XynA. The next step is the degradation of branch oligosaccharides by Aes and Ruxyn1; the latter would release D-arabinose to the media. The release of arabinose will start the second circuit. This circuit is regulated by an pBAD/ara promoter and would promote the expression of GRE3 and an inhibitor for the first circuit promoter. The gradual inhibition of the first circuit would allow the display of GRE3 without compromising membrane stability. Once the arabinose is consumed, the expression and the inhibition of the first and second circuit respectively will return to their original state.
 +
                        </h4>
 +
                        <br>
 +
                        <h3> Downstream </h3>
 +
                        <br>
 +
                        <h4>
 +
                            The downstream processing of xylitol production method will use a series of purification steps to ensure that all viable cells used during the fermentation stage are removed. Furthermore, this bioprocess will be carried out under the conditions set out by the FDA’s good manufacturing practice guidelines. Stringent validation, quality assurance and quality control steps will ensure that the bio-products are responsibly contained and disposed and that the final product is safe for consumption.
 +
                        </h4>
 +
                        <br>
 +
                        <center> <img src = "https://static.igem.org/mediawiki/2016/e/e1/T--UCL--BioProcess.png"> </center>
 +
                        <br>
 +
 
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
Line 164: Line 212:
 
                 </div>
 
                 </div>
  
                <br>
 
                <br>
 
  
 
                 <div class="row">
 
                 <div class="row">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
  
                         <div id="team" class="vertical-scroll-section">
+
                         <div id="market_analysis" class="vertical-scroll-section">
 
                             <div class="content">
 
                             <div class="content">
  
                                <h2> <center> 5. Team </center> </h2>
+
                        <h2> <center> 6. Market Analysis  </center> </h2>
                                <br>
+
                        <br>
                                <h4> Our multidisciplinary team consists of developers, biologists and entrepreneurs and can be broadly stratified into product development and business development. The current team was formed at the Cambridge University Technology and Enterprise Club’s 2016 Bio hackathon. Our 4 co-founding members are working to establish AlphaBrick as an incorporated software company. </h4>
+
                        <h4>
                                <br>
+
                            Although our proposed process is innovative, the product itself has strong competition from other xylitol manufacturers and even other commercially available sweeteners. Because of this, we have undertaken an analysis of the market as it is necessary to establish and develop a competitive marketing campaign. In order to design an efficient marketing strategy, we identified the market opportunities in the two biggest industries for the commercialization of xylitol: Food and Pharma.
                                <h4> Our product development team consists of Kelvin Zhang, Evgeny Saveliev and Shannon Doyle. With 8 years of coding experience, Kelvin is a freelance software developer. Kelvin works to build AlphaBrick’s back end code. Having studied natural sciences and as a seasoned programmer, Evgeny is currently works in software development for AiC. Evgeny works on front-end development, building the user-interface for AlphaBrick. As a recent UCL Pharmacology graduate, Shannon has been using her knowledge of laboratory protocols to help shape AlphaBrick’s interface with cloud laboratories.   Together, Kelvin and Evgeny have the necessary expertise to develop our platform, while Shannon’s biology expertise informs the platform’s output. </h4>
+
                        </h4>
                                <br>
+
                        <br>
                                <h4> Our business development is spearheaded by Hana Janebdar, a serial entrepreneur.  Hana draws on her experience of the biotech landscape and lean methodology to carve out AlphaBrick’s product and business concept. Hana’s role involves exploring applications and potential markets for the platform, assessing feedback on our product and refining the product specification through active market research. </h4>
+
                        <h3> Alternative Sweeteners Market </h3>
                                <br>
+
                        <br>
                                <h3> Team Member Profiles </h3>
+
                        <h4>
                                <br>
+
                            According to Transparency Market Research, the global alternative sweeteners market has an estimated Compound Annual Growth Rate (CAGR) of 4.2% between 2015 and 2021. In 2014, this market was valued in USD 11.5 billion and it is expected to reach USD 15.4 bn by 2021. These numbers are driven by an increasing awareness of calorie consumption along with a growing number of diabetic patients. However, the market is restrained by regulations over the use of certain chemicals and ingredients.
                                <center> <img src = "https://static.igem.org/mediawiki/2016/c/c5/T--UCL--alphabricktaeam.png" > </center>
+
                        </h4>
                                <Br>
+
                        <br>
                                <h4> Kelvin Zhang </h4>
+
                        <h4>
                                <br>
+
                            For this group of products, the North America region was the leading market in 2014 and is poised to sustain its dominance with a CAGR of 3.6% between 2015 and 2021. Despite the lead of the North American market, the Asia Pacific region would be the major contributors to the global alternative sweeteners market; in China and India alone, the expected CAGR are set to be 3.4% and 6.0% respectively.
                                <h4> Kelvin is an aspiring software engineer with a strong passion for web development He has accumulated a large amount of technical experience in recent years from working on software projects both at home and abroad. His diverse skillset also includes Linux server management and web application security, the latter in which he has attained several achievements. He works to develop AlphaBrick’s back-end using PHP + Laravel. </h4>
+
                        </h4>
                                <br>
+
                        <br>
                                <h4> Evgeny Saveliev </h4>
+
                        <h3> Xylitol Market</h3>
                                <br>
+
                        <br>
                                <h4> Evgeny is a University of Cambridge Natural Sciences graduate. Evgeny is a self-taught programmer, with significant experience in Scientific Computing and Numerical methods. Evgeny has been working with Apps in CADD (AiC), a civil engineering and software development company. Evgeny carries out front-end development for AlphaBrick, making sure the user-interface is accessible and intuitive. </h4>
+
                        <h4>
                                <br>
+
                            As an alternative sweetener, xylitol has been proven to be very useful because of its low-caloric and tooth-decaying prevention properties. These advantages are expected to increase the demand of xylitol in the next years. As reported by PRNewswire, the xylitol global market was estimated at 161.5 metric tons and a valuation of USD 670 million in 2013. Moreover, this market is expected to reach around 242 metric tons valued above USD 1 billion by 2020, driven by a CAGR of 6.0% in both metrics.
                                <h4> Shannon Doyle </h4>
+
                        </h4>
                                <br>
+
                        <br>
                                <h4> Shannon is a UCL graduate of Pharmacology and has been working to ensure that AlphaBrick can provide an easy to use interface with cloud laboratories. Shannon bringer her knowledge of lab work flows and programming to help write the protocols for the automated creations of user designs. </h4>
+
                        <h4>
                                <br>
+
                            From all the food industry, it is estimated confectionery and chewing gum manufacturers consumed nearly 80% of xylitol production at 2010. Based on this trend, the chewing gum industry is projected to be largest consumer of xylitol by 2020, using around 163 metric tons or 67% of the global xylitol production.
                                <h4> Hana Janebdar </h4>
+
                        </h4>
                                <br>
+
                        <br>
                                <h4> Hana Janebdar is a graduate of Imperial College London and Biochemical Engineering from UCL. Hana’s experience includes numerous positions within the biotech industry and as an active member of the London startup community, she has previously co-founded a medical device company. Hana is a student member of the UCL iGEM 2016 team and works to develop the product concept, providing the biology input needed for AlphaBrick while also working to develop AlphaBrick’s business proposition. </h4>
+
                        <h4>
                                    <br>
+
                            In addition to the food industry, it is important to mention the relevance of xylitol for the healthcare industry, as it is used in numerous products such as syrups, tonics and vitamin supplements. According to Technavio, the pharmaceutical industry represented a market share of 10.86% in 2010. Even though this percentage is minimal compared to the 15.01% and 67.24% of the confectionery and chewing gum industry in the same year respectively, the unique properties of xylitol compared to other similar molecules makes it an interesting bet for the pharmaceutical industry.
                                    <h4> Advisory Board </h4>
+
                        </h4>
                                    <br>
+
                        <br>
                                    <h4> AlphaBrick has been working to secure an advisory board to provide the essential advice needed to shape its vision for the future. AlphaBrick will be bringing on board, a scientific advisor and biotech business consultant. So far Alphabrick has been advised by members of UCL’s department of Biochemical Engineering and mentors from the Judge Business School which includes senior staff from the biotechnology industry. </h4>
+
                        <h4>
 +
                            If divided by regions, Europe is currently the largest market for xylitol according to Technavio. One of the reasons for its high-adoption rate is the rise of sugar prices. However, just as other alternative sweeteners, the Asia region is promising for the marketing of xylitol.
 +
                        </h4>
 +
                        <br>
 +
                        <h3> Competitors</h3>
 +
                        <br>
 +
                        <h4>
 +
                            Because of the current demand for xylitol and the positive market trend, many chemical companies around the world have become manufacturers of this sugar polyol. This market has been consolidated by rapid technological innovations and fluctuations in the consumer preferences, factors leading to increasing competition.
 +
                        </h4>
 +
                        <br>
 +
                        <h4>
 +
                            As reported by Technavio, the leading vendors of xylitol are Dupont, Cargill, CSPC Shengxue Glucose, Ingredion, and Mitsubishi Shoji Foodtech; other relevant vendors in this market are Zuchem, Hangzhou Shouxin Biological Technology, Novagreen, Tata Chemicals, Roquette Frères, and Thomson Biotech.
 +
                        </h4>
 +
                        <br>
  
 
                             </div>
 
                             </div>
Line 211: Line 270:
 
                 </div>
 
                 </div>
  
                <br>
 
                <br>
 
  
 
                 <div class="row">
 
                 <div class="row">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
  
                         <div id="funding" class="vertical-scroll-section">
+
                         <div id="marketing" class="vertical-scroll-section">
 
                             <div class="content">
 
                             <div class="content">
  
                                <h2> <center> 6. Funding </center> </h2>
+
                        <h2> <center> 7. Marketing  </center> </h2>
                                <h3> Milestones </h3>
+
                        <br>
                                <br>
+
                        <h4>
                                <h4> Our key milestones until the launch of the alpha version of our product focus on an initial proof-of-concept prototype for α-testing. Feedback and further development of our business model through customer interviews will shape our understanding and ability to prepare for our first round of investment fundraising. Our β version will be ready for launch in April 2017 while the launch of our first commercial version which will generate a revenue stream is set to launch by the end of June 2017. </h4>
+
                            Having considered the present status of the xylitol market and its growth prospects, we consider two marketing strategies for the food and pharmaceutical industries respectively.
                                <br>
+
                            After discussing with stakeholders in the food industry, specifically the confectionery industry, we found one of the most limiting feature of xylitol is its particular flavour. According to confectionery manufacturers, they show preference for xylitol in their products with citrus or mint flavours, whilst they mainly avoid its use in other products such as dark chocolate alone. However, they mention that this decision is mainly subjective and some people might find the xylitol-sweetened products likeable. This challenge could be overcome by developing a mixture of xylitol with other low-caloric sweeteners that can disguise its distinctive flavour without diminishing its properties.
                                <center> <img src = "https://static.igem.org/mediawiki/2016/b/bf/T--UCL--alphabrick8.png"> </center>
+
                        </h4>
                                <br>
+
                        <br>
                                <h3> Cost Analysis </h3>
+
                        <h4>
                                <br>
+
                            Another possible way to market our product in the food industry is to emphasise that it is environmental friendlier than other artificial sweeteners. The perception of natural over artificial for this type of products has increased in the last years, and has become a steady trend. Furthermore, its tooth-decay defying qualities are not found in other sweeteners and so this can be used to our advantage as part of our marketing strategy.
                                <h4> We presented Alphabrick to investors, VCs, startup founders and academics at the 2016 Technology Ventures Conference before being selected as the winners of the UK’s biggest biohackathon and recipients of the £1500 first prize to develop our product further. We were then fast-tracked to the Judge Business School’s prestigious Accelerator programme to bring Alphabrick to market by 2017. </h4>
+
                        </h4>
                                <br>
+
                        <br>
                                <h4> Using the award money from the CUTEC Biohackathon, our cash flow projection for the first 7 months indicates that we will have sufficient resources to fund development of our product. In the 6th month we will be poised for applying our first round of pre-seed investor funding for subsequent progression to the release of our alpha and beta versions. </h4>
+
                        <h4>
                                <br>
+
                            For the pharmaceutical sector, the commercialisation of xylitol has to be different. The regulations in this industry demand a product of higher purity. Because our isolation process excludes any remnants of cell debris and uses several filtration steps, we can commercialise our product as GMP compliant. This feature would help the pharmaceutical companies to fulfil most of the regulatory bodies (e.g. FDA, CE, etc.) requirements.
                                <center> <img src = "https://static.igem.org/mediawiki/2016/a/a6/T--UCL--alphabricktable.png" > </center>
+
                        </h4>
                                <br>
+
                        <br>
                                <h3> Funding Strategy</h3>
+
                            </div>
                                    <br>
+
                        </div>
                                    <h4> Our funding strategy for the next 6 months after January of 2017 focuses on obtaining non-dilutive grants and awards. Our £1500 award as the winning team of the CUTEC 2016 Biohackathon will burn out by February 2017, as will the resources of our founders to maintain themselves while working on this startup. We are exploring further funding opportunities through the Accelerate Cambridge programme.  This will predominantly fund product development, and administrative fees for IP protection. </h4>
+
                    </div>
                                    <br>
+
                </div>
                                    <h4> As the bulk of the cost of product development, after the launch in January 2017, is composed of the salaries of full time staff, we aim to raise pre-seed angel investment to take Alphabrick through its alpha and beta testing phases. By the beginning of February 2017 will aim to have raised £20,000. Should we obtain sufficient funds, we will be looking for our first round of seed investor funding to scale up and roll out our marketing strategy for June of 2017. As our current business model centres on a subscription model for premium features, we envisage that later stage product development will come from the income generated from subscription sales for our premium features in the region of £32.99 which is the current market standard for our type of software tool.  </h4>
+
  
                                    <br>
 
                                    <center> <img src = "https://static.igem.org/mediawiki/2016/2/27/T--UCL--alphabrick2table.png" > </center>
 
                                    <br>
 
  
 +
                <div class="row">
 +
                    <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
  
                                    <br>
+
                        <div id="business" class="vertical-scroll-section">
                                    <h4> We project that sales will initially be small in number as early adopters start to use our platform. Following a successful fundraising round for seed investment, Alphabrick will roll out a marketing campaign to drive sales and begin generation of revenue so that the company can break even and start to make a profit. Assuming a further, £40,000 is raised in the seed-fund round and that two more full time staff are added to the team, we will only have to make an average of 157 client subscription sales to break even by the end of 2018. </h4>
+
                            <div class="content">
                                    <br>
+
                                    <h3> Exit Strategy </h3>
+
                                    <br>
+
                                    <h4> We would only consider exiting this start-up after achieving a worthy market valuation. In the meantime, we intend to continue to establish and run the business until a suitable and sizable offer is made. At a later stage we anticipate that offers are likely to come from automated laboratory businesses such as Transcriptic. Automated laboratories are seeking to transform the labour-intensive scientific process. As part of their growth model these businesses are likely to want to acquire a platform with a strong user-base that makes their technology more accessible. </h4>
+
                                    <br>
+
                                    <h4> In the event that the proposed plan is not successful, we will endeavour to adjust our plan accordingly. If this also fails, we will implement measures to exit the business with minimal damage to all stake-holders. Tangible assets will be liquidated to cover any outstanding debts. Definitions of "successful" and time limits for achieving milestones are included in AlphaBrick's Co-founder's Agreement. </h4>
+
  
 +
                        <h2> <center> 8. Business Environment    </center> </h2>
 +
                        <br>
 +
                        <h3> STEEPLE Analysis </h3>
 +
                        <br>
 +
                        <h4>
 +
                            A consideration of the long-term, external and internal, issues that may arise during Xweet’s progression to a functioning production company is undertaken here to evaluate Xweet’s longer-term business environment.  A STEEPLE framework which in its augmented form encompasses a PEST (political, economic, social and environmental) and SWOT (strengths, opportunities, weaknesses, threats) analysis, is used her evaluate external and internal points of possible concern for Xweet.
 +
                        </h4>
 +
                        <br>
 +
                        <center> <img src = "https://static.igem.org/mediawiki/2016/8/8b/T--UCL--XweetSteeple.png "> </center>
 +
                        <br>
 +
                        <h3> Regulation </h3>
 +
                        <h4>
 +
                            Our xylitol product will be classified as a food additive and would most likely be regulated by the EU based on the agreements decided by member states outlined by Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997.
 +
                        </h4>
 +
                        <br>
 +
                            </div>
 +
                        </div>
 +
                    </div>
 +
                </div>
 +
 +
                <div class="row">
 +
                    <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 +
 +
                        <div id="management" class="vertical-scroll-section">
 +
                            <div class="content">
 +
 +
                        <h2> <center> 9. Management  </center> </h2>
 +
                        <br>
 +
                        <h4>
 +
                            The competency of our management team is vital to the success of our product. We have identified the team members that will be required to set up Xweet as a xylitol production company. Our management organogram below shows the vital functional departments we need to drive the success of our venture.
 +
                        </h4>
 +
                        <br>
 +
                        <center> <img src = " https://static.igem.org/mediawiki/2016/7/72/T--UCL--Management.png"> </center>
 +
                        <br>
 
                             </div>
 
                             </div>
 
                         </div>
 
                         </div>
Line 260: Line 343:
 
                     </div>
 
                     </div>
 
                 </div>
 
                 </div>
 +
 +
 +
                <div class="row">
 +
                    <div class="col-md-8 col-md-offset-2 ess-template-general animate-box">
 +
 +
                        <div id="financial" class="vertical-scroll-section">
 +
                            <div class="content">
 +
 +
                        <h2> <center> 10.  Financial Data </center> </h2>
 +
                        <br>
 +
                        <h4>
 +
                            Our following financial estimates are based on the assumption that we will make sales to 5% of the total addressable xylitol market of $670 million each year following an initial 3-year time period in which we set up our facility and obtain regulatory approval. This cost estimation will elucidate the amount of investment that this venture will require. For the purposes of this exercise cost estimates of raw materials, as well as the selling price, are taken estimates from comparative products in the biochemical manufacturing industry. As we know the cost of our raw materials and selling price will be lower, this provides us with a worst case scenario, contributing to a risk mitigation strategy.  Although revenues would start in the 4th year, due to the high cost of facility set up and equipment cost and installation, we are likely to break even in the 10th year of this venture. Our annual profit will then steadily climb.
 +
                        </h4>
 +
                        <br>
 +
                        <center> <img src = "https://static.igem.org/mediawiki/2016/5/5c/T--UCL--BreakEven.png"> </center>
 +
                        <br>
 +
                            </div>
 +
                        </div>
 +
                    </div>
 +
                </div>
 +
  
 
             </div>
 
             </div>

Revision as of 03:59, 20 October 2016

<!DOCTYPE html>

UCL iGEM 2016 | BioSynthAge

XWEET

1. Executive Summary


Xylitol is a sugar polyol that has been used in the food industry as a low-caloric sweetener. It has been reported to have multiple beneficial health effects such as the prevention of dental caries, osteoporosis, and acute otitis media. Currently, xylitol is commonly produced by the chemical reduction of xylose presented in xylans. However, this process represents substantial costs for the industry. We have designed a genetic circuit for the expression of the necessary enzymes for the biological production of xylitol from lignocellulose hydrolysates for expression in E. coli for fermentation and subsequent processing.


We have also created a comprehensive first iteration of a business plan for the production of Xweet, a key ingredient in tooth-decay defying sweets. We have filed a provisional patent and trademarked our more environmentally friendly method for the production of Xweet. Adopting a lean method, we have engaged extensively with the confectionary industry, prototyping Xweet confectionery and setting out a pathway for commercial success.



2. The problem explored


Through our engagement with our local elderly community we identified a demand for tea-time treats that did not cause tooth-decay or imbalances in sugar levels. Adopting a lean method, we have engaged extensively with the confectionary industry to explore London’s sugar-substituted sweet landscape to confirm this as a wider demand. Our extensive literature search drew our attention to xylitol, a sugar substitute with widely-reported health benefits but an environmentally unfavorable and expensive production process. Xylitol is a key ingredient in tooth-decay defying sweets. Speaking to the UK’s confectionary manufacturers, we confirmed demand for xylitol produced in a less expensive and more environmentally friendly way.


Demand for tooth-decay defying treats from end users


London’s ageing population have a sweet tooth. Reports show that this is due to the impact that ageing has on our taste buds. Over time our taste buds decrease in number and become less sensitive. This is compounded by the effect of age-related diseases such as Alzheimer’s and Parkinson’s Disease, with the loss of taste and smell actually becoming increasingly important in the diagnosis of these disease. This drives the increasingly sweet tooth of the ageing population which in turn drives a negative impact on the oral health of this population. The oral disease burden, of which a big part is attributable our ageing population, is causing the total oral health expenditure within the EU to rise to an enormous €93 billion in 2020. There is therefore a push in public health policy towards preventative solutions that minimize bad oral health manifested in large parts as dental caries. This demand for tooth-decay defying sweets was therefore flagged up to us through our engagement with the elderly community. They described their need for sweet treats and oral health as a constant pain throughout their ageing process.



Demand for tooth-decay defying treats from confectionery retailers

We confirmed this demand for tooth-decay defying treats through interviews with London’s sweet landscape. We identified that these outlets were experiencing a shift in their customer demands such that there is an increasingly underserved proportion of health-conscious sweet lovers. Some of the sweet shops that we interviewed made their own sweets, while most bought their sweets from confectionary manufacturers. While the total EU and US confectionary market it worth €66.75 billion, the healthy confectionary market has been increasing its share of this overall market in recent years, putting the latest market share estimate within the UK at 11%. The growth of the healthy confectionary market is 16% higher than the total average growth of the entire confectionary market. These confectionary outlets provided us with a list of sugar-substitutes that customers ask for and that are used in the production of these sweets. We partnered with staff to identify xylitol through this market research and an extensive literature search as a candidate for meeting this demand. D-Xylitol is a sugar polyol that has been used in the food industry as a low-caloric sweetener. It also has been reported as having multiple beneficial health effects such as the prevention of dental caries, osteoporosis, and acute otitis media.




Demand for tooth-decay defying ingredients from confectionery manufacturing industry


Our literature research highlighted the potential of xylitol for use in tooth-decay defying sweets. It’s health benefits and positive impact on dental caries have been widely reported. We explored how xylitol is used in confectionary manufacturing to understand how more confectionary manufacturers can be enabled to use xylitol in their production processes. By visiting a chocolate manufacturing company, discussing their production process with the Operation Manager and observing their production process, we were able understand the decision making process in raw material procurement and the parameters for consideration of the material in the process. Most notably, we discovered that manufacturers prefer to use xylitol over other sugar substitutes such as coconut sugar as xylitol’s high melting temperatures makes it a manufacturer’s dream when making chocolate treats as machinery is not clogged up with caramel. However, the manufacturers hold back from using xylitol because of its associated costs and environmental impact.



3. Our Solution

We have therefore identified trapped value where in the value chain from feedstock to production of tooth-decay defying treats. We are best placed to solve this problem and have devised a plan for the production of xylitol, using synthetic biology and biochemical engineering processes, that reduces the impact on the environment and decreases associated costs. Our solution aims to supply a big proportion of the global market demand for more than 125,000 tonnes of xylitol per annum.




Our solution for the production of xylitol for supply to confectionery manufacturer involves a synthetic gene circuit in E. coli for extracellular secretion of xylitol following processing of xylan from agricultural waste in the upstream process. The downstream process involves a series of biochemical extraction and purification steps, using drastically less energy than the chemical process for xylitol production. Our xylitol product, Xweet, can be used to produce tooth-decay defying confectionery treats that utilise xylitol, at a lower price and incredibly similar taste to conventionally sugared treats.


We prototyped a potential treat that could be made with our xylitol product. We cooked up fudge using conventional brown sugar and xylitol. We asked UCL students to compare the tastes of our two batches, two identify the better tasting batch and the one that they thought contained xylitol. 100% of all participants guessed incorrectly, failing to identify the xylitol batch correctly. This lends support to the potential for xylitol to replace sugar in a vast number of confectionery products.




Using our upstream technology in a novel method for the production of xylitol from agricultural waste reduces the cost of the final product and the environmental impact. This therefore means that we are able to sell xylitol to confectionary manufacturers and the pharmaceutical industry for who the value proposition of reduced cost of raw materials and the reduced carbon footprint of their final product lifecycle contributes to the increase in profit margins. By making xylitol purchasing cheaper, moreover, we are empowering confectionary manufacturers to meet the demands of an ageing population for tooth-decay defying treats. We therefore have a unique and defendable business case.

4. Intellectual Property

Because of its technological relevance and its disclosure in this event, having an intellectual property strategy was crucial for the commercial aspects of the project. This approach has been confirmed after several discussions with numerous potential investors and advisers. Two important intellectual property figures were considered for this project, a patent and a trademark.


Patent


Initially, we performed a search in the database (Espacenet) from the European Patent Office. The results were encouraging because no result was similar to our invention after using (in different combinations) the keywords: xylitol, cell, surface, display. However, considering the possibility of not complying with the novelty feature, we searched for scientific articles that could describe a similar technology. From the results, we found that Guirimand et al. published in 2015 a similar system. The researchers reported the surface display of four enzymes (Xylose reductase, ß-glucosidase, xylosidase and xylanase) on yeast for the conversion of xylans into xylitol. Despite its likeness, our proposed project differs in (1) the displayed enzymes, (2) the host organism, (3) the oscillating phenotype of the enzymatic expression. Following this, we found that our invention could fulfill the three patent features and therefore our invention was fully patentable. This intellectual property search allowed us to define the claims for our patent application. We filed a provisional patent application with the UK Intellectual Property Office using the presented form with the application number 1616500.3. The relevant documents for this application are presented below:


This intellectual property search allowed us to define the claims for our patent application. We filed a provisional patent application with the UK Intellectual Property Office using the presented form with the application number 1616500.3. The relevant documents for this application are presented below:


1. Filed Form

2. Receipt


We are currently working on an international patent application (PCT) for our invention. This strategy grants us additional time for starting patent applications simultaneously in 140 countries.


Trademark


Continuing with our intellectual property strategy, we have been working on filing a trademark application with the UK Intellectual Property Office for the brand and the logo of our final product, Xweet. This allows us to distribute an early version of the product to different stakeholders while building a product identity.

5. Manufacturing operations


Upstream: Feedstock


One challenge in the production of Xylitol is to find an adequate source. As mentioned before, purified D-Xylose is used for the chemical and enzymatic production. However, the use of agricultural waste for the manufacture of Xylitol has become a milestone in this field.


Most of the agricultural waste can be divided in cellulose, hemicellulose, and lignocellulose. Lignocellulosic biomasses (LBs) are widespread, abundant, renewable, cost-effective, and economical sources of polysaccharides, which can be used for xylitol production. These sources include agricultural, agro-industrial, and forestry These residues contain lignocellulose, organic matter that is mainly composed of cellulose (34–50%), hemicellulose (19–34%), lignin (11–30%), and smaller amounts of pectin, protein, extractive, and ashes. The composition of these components differs with the source of plant species, age, and growth conditions. The most abundant heterogeneous polymer of LBs is hemicellulose, which comprises of pentoses (xylose and arabinose), hexoses (mannose, glucose, and galactose), and residues. Sugar acids. We are considering the use of the LB hydrolysates as Xylan source and fundamental part of the proposed system.


Upstream: Inoculum strain for bioconversion during fermentation

Currently, D-Xylitol is commonly produced by the chemical reduction of D-Xylose presented in xylans in the presence of a nickel catalyst at elevated temperature and pressure. However, this process represents substantial costs for the industry. A proposed alternative for the chemical hydrolysis is the conversion of this pentose by the use of enzymes or microorganisms. Nonetheless, the biological fermentation presents some issues such as accumulation of the metabolite at toxic levels or challenges with the purification process. Additionally, the use of enzymes may represent a higher cost because of the production and purification of such proteins.


The bioprocess for xylitol production that we are presenting is based on the expression of cell surface displayed enzymes. The enzymes in this system are described in the next table:



In this case, the enzymes involved in the degradation of xylan and the subsequent xylitol transformation are fused to the ß-domain of the autotransporter EspP. The fusion proteins would be expressed in E. coli and be able to anchor to the outer membrane. The advantage of this system is the avoidance of purification steps. However, some issues should be taken on account such as required cofactors or the presence of disulphide bonds.


Because of possible membrane instability, the expression of these enzymes is controlled by a genetic circuit. The proposed genetic circuit would function as an oscillator by expressing constitutively on the surface the enzymes XynA, Aes and Ruxyn1. The expression of these enzymes would trigger the degradation of Xylans into monomers from the lignocellulosic hydrolysates by XynA. The next step is the degradation of branch oligosaccharides by Aes and Ruxyn1; the latter would release D-arabinose to the media. The release of arabinose will start the second circuit. This circuit is regulated by an pBAD/ara promoter and would promote the expression of GRE3 and an inhibitor for the first circuit promoter. The gradual inhibition of the first circuit would allow the display of GRE3 without compromising membrane stability. Once the arabinose is consumed, the expression and the inhibition of the first and second circuit respectively will return to their original state.


Downstream


The downstream processing of xylitol production method will use a series of purification steps to ensure that all viable cells used during the fermentation stage are removed. Furthermore, this bioprocess will be carried out under the conditions set out by the FDA’s good manufacturing practice guidelines. Stringent validation, quality assurance and quality control steps will ensure that the bio-products are responsibly contained and disposed and that the final product is safe for consumption.



6. Market Analysis


Although our proposed process is innovative, the product itself has strong competition from other xylitol manufacturers and even other commercially available sweeteners. Because of this, we have undertaken an analysis of the market as it is necessary to establish and develop a competitive marketing campaign. In order to design an efficient marketing strategy, we identified the market opportunities in the two biggest industries for the commercialization of xylitol: Food and Pharma.


Alternative Sweeteners Market


According to Transparency Market Research, the global alternative sweeteners market has an estimated Compound Annual Growth Rate (CAGR) of 4.2% between 2015 and 2021. In 2014, this market was valued in USD 11.5 billion and it is expected to reach USD 15.4 bn by 2021. These numbers are driven by an increasing awareness of calorie consumption along with a growing number of diabetic patients. However, the market is restrained by regulations over the use of certain chemicals and ingredients.


For this group of products, the North America region was the leading market in 2014 and is poised to sustain its dominance with a CAGR of 3.6% between 2015 and 2021. Despite the lead of the North American market, the Asia Pacific region would be the major contributors to the global alternative sweeteners market; in China and India alone, the expected CAGR are set to be 3.4% and 6.0% respectively.


Xylitol Market


As an alternative sweetener, xylitol has been proven to be very useful because of its low-caloric and tooth-decaying prevention properties. These advantages are expected to increase the demand of xylitol in the next years. As reported by PRNewswire, the xylitol global market was estimated at 161.5 metric tons and a valuation of USD 670 million in 2013. Moreover, this market is expected to reach around 242 metric tons valued above USD 1 billion by 2020, driven by a CAGR of 6.0% in both metrics.


From all the food industry, it is estimated confectionery and chewing gum manufacturers consumed nearly 80% of xylitol production at 2010. Based on this trend, the chewing gum industry is projected to be largest consumer of xylitol by 2020, using around 163 metric tons or 67% of the global xylitol production.


In addition to the food industry, it is important to mention the relevance of xylitol for the healthcare industry, as it is used in numerous products such as syrups, tonics and vitamin supplements. According to Technavio, the pharmaceutical industry represented a market share of 10.86% in 2010. Even though this percentage is minimal compared to the 15.01% and 67.24% of the confectionery and chewing gum industry in the same year respectively, the unique properties of xylitol compared to other similar molecules makes it an interesting bet for the pharmaceutical industry.


If divided by regions, Europe is currently the largest market for xylitol according to Technavio. One of the reasons for its high-adoption rate is the rise of sugar prices. However, just as other alternative sweeteners, the Asia region is promising for the marketing of xylitol.


Competitors


Because of the current demand for xylitol and the positive market trend, many chemical companies around the world have become manufacturers of this sugar polyol. This market has been consolidated by rapid technological innovations and fluctuations in the consumer preferences, factors leading to increasing competition.


As reported by Technavio, the leading vendors of xylitol are Dupont, Cargill, CSPC Shengxue Glucose, Ingredion, and Mitsubishi Shoji Foodtech; other relevant vendors in this market are Zuchem, Hangzhou Shouxin Biological Technology, Novagreen, Tata Chemicals, Roquette Frères, and Thomson Biotech.


7. Marketing


Having considered the present status of the xylitol market and its growth prospects, we consider two marketing strategies for the food and pharmaceutical industries respectively. After discussing with stakeholders in the food industry, specifically the confectionery industry, we found one of the most limiting feature of xylitol is its particular flavour. According to confectionery manufacturers, they show preference for xylitol in their products with citrus or mint flavours, whilst they mainly avoid its use in other products such as dark chocolate alone. However, they mention that this decision is mainly subjective and some people might find the xylitol-sweetened products likeable. This challenge could be overcome by developing a mixture of xylitol with other low-caloric sweeteners that can disguise its distinctive flavour without diminishing its properties.


Another possible way to market our product in the food industry is to emphasise that it is environmental friendlier than other artificial sweeteners. The perception of natural over artificial for this type of products has increased in the last years, and has become a steady trend. Furthermore, its tooth-decay defying qualities are not found in other sweeteners and so this can be used to our advantage as part of our marketing strategy.


For the pharmaceutical sector, the commercialisation of xylitol has to be different. The regulations in this industry demand a product of higher purity. Because our isolation process excludes any remnants of cell debris and uses several filtration steps, we can commercialise our product as GMP compliant. This feature would help the pharmaceutical companies to fulfil most of the regulatory bodies (e.g. FDA, CE, etc.) requirements.


8. Business Environment


STEEPLE Analysis


A consideration of the long-term, external and internal, issues that may arise during Xweet’s progression to a functioning production company is undertaken here to evaluate Xweet’s longer-term business environment. A STEEPLE framework which in its augmented form encompasses a PEST (political, economic, social and environmental) and SWOT (strengths, opportunities, weaknesses, threats) analysis, is used her evaluate external and internal points of possible concern for Xweet.



Regulation

Our xylitol product will be classified as a food additive and would most likely be regulated by the EU based on the agreements decided by member states outlined by Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997.


9. Management


The competency of our management team is vital to the success of our product. We have identified the team members that will be required to set up Xweet as a xylitol production company. Our management organogram below shows the vital functional departments we need to drive the success of our venture.



10. Financial Data


Our following financial estimates are based on the assumption that we will make sales to 5% of the total addressable xylitol market of $670 million each year following an initial 3-year time period in which we set up our facility and obtain regulatory approval. This cost estimation will elucidate the amount of investment that this venture will require. For the purposes of this exercise cost estimates of raw materials, as well as the selling price, are taken estimates from comparative products in the biochemical manufacturing industry. As we know the cost of our raw materials and selling price will be lower, this provides us with a worst case scenario, contributing to a risk mitigation strategy. Although revenues would start in the 4th year, due to the high cost of facility set up and equipment cost and installation, we are likely to break even in the 10th year of this venture. Our annual profit will then steadily climb.